USP25 regulates atherosclerosis by restricting RIPK1-mediated inflammatory responses

Key Points

• The aim is to investigate how USP25 influences atherosclerosis through the regulation of RIPK1-mediated inflammatory responses.
• Utilized genetic and pharmacological approaches to manipulate USP25 levels.
• Assessed inflammatory markers associated with RIPK1 activity.
• Performed in vivo and in vitro experiments to measure atherosclerotic plaque formation.
• Increased USP25 levels were linked to reduced inflammatory responses.
• Decreased RIPK1 activity was observed with higher USP25 expression.
• A significant reduction in atherosclerotic plaque size was noted in models with elevated USP25.